Clinical trial results:
Daratumumab (HuMax-CD38) Safety Study in Multiple Myeloma – Open-label, Dose-Escalation Followed by Open-Label, Single-Arm Study

Summary

EudraCT number	2007-003783-22
Trial protocol	DK SE NL
Global end of trial date	31 March 2017

Results information

Result version number	v1 (current)
This version publication date	15 April 2018
First version publication date	15 April 2018

Trial information

Trial identification

Sponsor protocol code	DARA-GEN501

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00574288
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Janssen Research & Development, LLC
Sponsor organisation address	920 Route, Raritan, United States, 08869
Public contact	Clinical Registry group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 March 2017
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	31 March 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of this study was to establish the safety profile of daratumumab when given as monotherapy in subjects with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment options.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Safety evaluations included for both Part 1 and Part 2 and were based on medical history, measurements of vital signs, and physical examinations, treatment emergent adverse events (TEAEs) and serious TEAEs, clinical laboratory tests. Electrocardiogram (ECG) findings also were performed to assess for potential toxicities.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	26 March 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Denmark: 30
Country: Number of subjects enrolled	Netherlands: 32
Country: Number of subjects enrolled	Sweden: 22
Country: Number of subjects enrolled	United States: 20
Worldwide total number of subjects	104
EEA total number of subjects	84

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	63
From 65 to 84 years	41
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

In total 104 subjects enrolled in this two part study. In Part 1, 32 subjects were treated with daratumumab in which twenty subjects received daratumumab at doses <4 mg/kg, while 3 subjects in each dose group received 4 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of daratumumab. In Part 2, 72 subjects were treated with daratumumab.

Period 1

Period 1 title	End of Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Part 1: Daratumumab Less Than (<) 4 mg/kg

Arm description:

Subjects were administered with 7 full intravenous (IV) infusion of 0.005, 0.05, 0.1, 0.5, 1 and 2 milligram per kilogram body weight (mg/kg) daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Arm type	Experimental
Investigational medicinal product name	Daratumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received 7 full intravenous (IV) infusion of 0.005, 0.05, 0.1, 0.5, 1 and 2 milligram per kilogram body weight
(mg/kg) daratumumab once weekly.

Arm title	Part 1:Daratumumab 4 mg/kg

Arm description:

Subjects were administered with 7 full IV infusion of 4 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Arm type	Experimental
Investigational medicinal product name	Daratumumab 4 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received 7 full IV infusion of 4 mg/kg daratumumab once weekly.

Arm title	Part 1:Daratumumab 8 mg/kg

Arm description:

Subjects were administered with 7 full IV infusion of 8 mg/kg daratumumab once weekly, along with this subjecs also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week

washout period.

Arm type	Experimental
Investigational medicinal product name	Daratumumab 8 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received 7 full IV infusion of 8 mg/kg daratumumab once weekly.

Arm title	Part 1:Daratumumab 16 mg/kg

Arm description:

Subjects were administered with 7 full IV infusion of 16 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Arm type	Experimental
Investigational medicinal product name	Daratumumab 16 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received 7 full IV infusion of 16 mg/kg daratumumab once weekly.

Arm title	Part 1:Daratumumab 24 mg/kg

Arm description:

Subjects were administered with 7 full IV infusion of 24 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Arm type	Experimental
Investigational medicinal product name	Daratumumab 24 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received 7 full IV infusion of 24 mg/kg daratumumab once weekly.

Arm title	Part 2: Daratumumab 8 mg/kg

Arm description:

Subjects were administered with 8 full IV infusions of 8 mg/kg daratumumab once weekly for 8 weeks, then every 2 weeks (q2w) for 16 weeks, then every 4 weeks (q4w) until the subject experienced disease progression or unmanageable toxicity whichever came first, along with this subjects also received methylprednisolone 100 mg IV before treatment and 20–25 mg methylprednisolone orally for 2 days after all full infusions.

Arm type	Experimental
Investigational medicinal product name	Daratumumab 8 mg/kg IV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received 8 mg/kg daratumumab weekly once for 8 weeks, then q2w for 16 weeks or until the subject experienced disease progression or unmanageable toxicity, whichever came first.

Arm title	Part 2: Daratumumab 16 mg/kg

Arm description:

Subjects were administered with 8 full IV infusions of 16 mg/kg daratumumab once weekly for 7 weeks, then every 2 weeks (q2w) for 14 weeks, then every 4 weeks (q4w) until the subject experienced disease progression or unmanageable toxicity whichever came first, along with this subjects also received methylprednisolone 100 mg IV before treatment and 20–25 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Arm type	Experimental
Investigational medicinal product name	Daratumumab 16 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received 8 full IV infusions of 16 mg/kg daratumumab once weekly for 7 weeks, then q2w for 14 weeks or until the subject experienced disease progression or unmanageable toxicity, whichever came first.

Number of subjects in period 1	Part 1: Daratumumab Less Than (<) 4 mg/kg	Part 1:Daratumumab 4 mg/kg	Part 1:Daratumumab 8 mg/kg
Started	20	3	3
Completed	0	0	0
Not completed	20	3	3
Adverse event, non-fatal	2	-	-
Other: progressive disease	17	2	3
Study Terminated By Sponsor	-	-	-
Unspecified	1	1	-
Lost to follow-up	-	-	-
Other: death	-	-	-

Number of subjects in period 1	Part 1:Daratumumab 16 mg/kg	Part 1:Daratumumab 24 mg/kg	Part 2: Daratumumab 8 mg/kg
Started	3	3	30
Completed	1	1	4
Not completed	2	2	26
Adverse event, non-fatal	-	1	-
Other: progressive disease	2	1	-
Study Terminated By Sponsor	-	-	-
Unspecified	-	-	-
Lost to follow-up	-	-	1
Other: death	-	-	25

Number of subjects in period 1	Part 2: Daratumumab 16 mg/kg
Started	42

Completed	14
Not completed	28
Adverse event, non-fatal	-
Other: progressive disease	-
Study Terminated By Sponsor	5
Unspecified	-
Lost to follow-up	2
Other: death	21

Baseline characteristics

Reporting groups

Reporting group title	Part 1: Daratumumab Less Than (<) 4 mg/kg

Reporting group description:

Subjects were administered with 7 full intravenous (IV) infusion of 0.005, 0.05, 0.1, 0.5, 1 and 2 milligram per kilogram body weight (mg/kg) daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1:Daratumumab 4 mg/kg

Reporting group description:

Subjects were administered with 7 full IV infusion of 4 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1:Daratumumab 8 mg/kg

Reporting group description:

Subjects were administered with 7 full IV infusion of 8 mg/kg daratumumab once weekly, along with this subjecs also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1:Daratumumab 16 mg/kg

Reporting group description:

Subjects were administered with 7 full IV infusion of 16 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1:Daratumumab 24 mg/kg

Reporting group description:

Subjects were administered with 7 full IV infusion of 24 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 2: Daratumumab 8 mg/kg

Reporting group description:

Subjects were administered with 8 full IV infusions of 8 mg/kg daratumumab once weekly for 8 weeks, then every 2 weeks (q2w) for 16 weeks, then every 4 weeks (q4w) until the subject experienced disease progression or unmanageable toxicity whichever came first, along with this subjects also received methylprednisolone 100 mg IV before treatment and 20–25 mg methylprednisolone orally for 2 days after all full infusions.

Reporting group title	Part 2: Daratumumab 16 mg/kg

Reporting group description:

Subjects were administered with 8 full IV infusions of 16 mg/kg daratumumab once weekly for 7 weeks, then every 2 weeks (q2w) for 14 weeks, then every 4 weeks (q4w) until the subject experienced disease progression or unmanageable toxicity whichever came first, along with this subjects also received methylprednisolone 100 mg IV before treatment and 20–25 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group values	Part 1: Daratumumab Less Than (<) 4 mg/kg	Part 1:Daratumumab 4 mg/kg	Part 1:Daratumumab 8 mg/kg
Number of subjects	20	3	3
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0

Adults (18-64 years)	11	2	2
From 65 to 84 years	9	1	1
85 years and over	0	0	0
Title for AgeContinuous Units: years			
arithmetic mean	61.8	64.0	61.3
standard deviation	± 9.24	± 2.00	± 6.11
Title for Gender Units: subjects			
Female	7	2	0
Male	13	1	3

Reporting group values	Part 1:Daratumumab 16 mg/kg	Part 1:Daratumumab 24 mg/kg	Part 2: Daratumumab 8 mg/kg
Number of subjects	3	3	30
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	3	2	21
From 65 to 84 years	0	1	9
85 years and over	0	0	0
Title for AgeContinuous Units: years			
arithmetic mean	53.0	59.0	58.6
standard deviation	± 1.73	± 9.54	± 10.05
Title for Gender Units: subjects			
Female	0	0	9
Male	3	3	21

Reporting group values	Part 2: Daratumumab 16 mg/kg	Total	
Number of subjects	42	104	
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	22	63	
From 65 to 84 years	20	41	
85 years and over	0	0	
Title for AgeContinuous Units: years			
arithmetic mean	63.8		
standard deviation	± 8.27	-	
Title for Gender Units: subjects			
Female	15	33	
Male	27	71	

End points

End points reporting groups

Reporting group title	Part 1: Daratumumab Less Than (<) 4 mg/kg

Reporting group description:

Subjects were administered with 7 full intravenous (IV) infusion of 0.005, 0.05, 0.1, 0.5, 1 and 2 milligram per kilogram body weight (mg/kg) daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1:Daratumumab 4 mg/kg

Reporting group description:

Subjects were administered with 7 full IV infusion of 4 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1:Daratumumab 8 mg/kg

Reporting group description:

Subjects were administered with 7 full IV infusion of 8 mg/kg daratumumab once weekly, along with this subjecs also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1:Daratumumab 16 mg/kg

Reporting group description:

Subjects were administered with 7 full IV infusion of 16 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1:Daratumumab 24 mg/kg

Reporting group description:

Subjects were administered with 7 full IV infusion of 24 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 2: Daratumumab 8 mg/kg

Reporting group description:

Subjects were administered with 8 full IV infusions of 8 mg/kg daratumumab once weekly for 8 weeks, then every 2 weeks (q2w) for 16 weeks, then every 4 weeks (q4w) until the subject experienced disease progression or unmanageable toxicity whichever came first, along with this subjects also received methylprednisolone 100 mg IV before treatment and 20–25 mg methylprednisolone orally for 2 days after all full infusions.

Reporting group title	Part 2: Daratumumab 16 mg/kg

Reporting group description:

Subjects were administered with 8 full IV infusions of 16 mg/kg daratumumab once weekly for 7 weeks, then every 2 weeks (q2w) for 14 weeks, then every 4 weeks (q4w) until the subject experienced disease progression or unmanageable toxicity whichever came first, along with this subjects also received methylprednisolone 100 mg IV before treatment and 20–25 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Primary: Number of Subjects with Adverse Events

End point title	Number of Subjects with Adverse Events[1]

End point description:

An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All-Treated Analysis Set included all enrolled subjects who

received at least 1 dose of study drug.

End point type	Primary

End point timeframe:

Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive statistical analysis was performed for this outcome measure.

End point values	Part 1: Daratumumab Less Than (<) 4 mg/kg	Part 1:Daratumumab 4 mg/kg	Part 1:Daratumumab 8 mg/kg	Part 1:Daratumumab 16 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	3	3	3
Units: Subjects	19	3	3	3

End point values	Part 1:Daratumumab 24 mg/kg	Part 2: Daratumumab 8 mg/kg	Part 2: Daratumumab 16 mg/kg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	3	30	42	
Units: Subjects	3	30	41	

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Response Rate (ORT)

End point title	Overall Response Rate (ORT)[2]

End point description:

Overall response defined as percentage of subjects who achieved sCR, CR ,VGPR or PR. Per IMWG criteria, sCR: defined as normal FLC ratio, and PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry; CR: Negative immunofixation on serum, urine and disappearance of tissue plasmacytomas and < 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or >= 90% reduction in serum M-protein plus urine M-protein level < 100mg/24 hrs; PR: >= 50% reduction of serum M-protein and reduction in 24 hrs urinary M-protein by >= 90% or <200 mg/24 hrs; if serum and urine M-protein are not measurable, decrease of >=50% in difference between involved and uninvolved FLC levels is required in place of M-protein criteria. All-Treated analysis set included subjects received at least 1 dose of study drug. Part 1, subjects treated with >=4 mg/kg daratumumab used for efficacy and <4 mg/kg considered therapeutic level.

End point type	Secondary

End point timeframe:

Up to Week 28 (for Part 1) and Week 27 (for Part 2)

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint was planned to be reported for the specified arms only.

End point values	Part 1:Daratumumab 4 mg/kg	Part 1:Daratumumab 8 mg/kg	Part 1:Daratumumab 16 mg/kg	Part 1:Daratumumab 24 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: Percentage of subjects				
number (confidence interval 95%)	33.3 (0.8 to 90.6)	0 (0 to 0)	33.6 (0.8 to 90.6)	66.7 (9.4 to 99.2)

End point values	Part 2: Daratumumab 8 mg/kg	Part 2: Daratumumab 16 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	42		
Units: Percentage of subjects				
number (confidence interval 95%)	10.0 (2.1 to 26.5)	35.7 (21.6 to 52.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Time to Response

End point title	Part 1: Time to Response[3]

End point description:

Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Kaplan-Meier method was used to estimate the distribution of time to response and time to best response. All-Treated Analysis Set included enrolled subjects received at least 1 dose of study drug. Here '-99999' and '99999' means 'not estimable' due to less number of subjects with response. Daratumumab 4 mg/kg arm median and upper limit of CI was not estimable due to less number of subjects with events. 3 subjects on 16 mg/kg, 1 subject had event, median was set to uncensored value of time to event no lower or upper bound of 95% CI . For 8mg/kg, median and CI was not estimable due to less number of subjects.

End point type	Secondary

End point timeframe:

Up to Week 28

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint was planned to be reported for the specified arms only.

End point values	Part 1:Daratumumab 4 mg/kg	Part 1:Daratumumab 8 mg/kg	Part 1:Daratumumab 16 mg/kg	Part 1:Daratumumab 24 mg/kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	3
Units: Months				
median (confidence interval 95%)				
Time to first response	99999 (1.2 to 99999)	99999 (-99999 to 99999)	8.4 (-99999 to 99999)	1.9 (0.5 to 1.9)

Time to best response	99999 (1.2 to 99999)	99999 (-99999 to 99999)	8.4 (-99999 to 99999)	1.9 (0.5 to 1.9)

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Time to Progression (TTP)

End point title	Part 2: Time to Progression (TTP)[4]

End point description:

TTP was defined as the number of days from the date of first infusion (Day 1) to the date of first record of disease progression. Disease progression (IMWG criteria): increase of 25 percent (%) from lowest response level in Serum M-component and/or (the absolute increase must be >=0.5 g/dL); urine M-component and/or (the absolute increase must be >=200 mg/24 hour; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase must be >10 mg/dL); Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder. Median TTP was estimated by using the Kaplan-Meier method. All-Treated Analysis Set included enrolled subjects received at least 1 dose of study drug. Here "99999" indicates no upper limit of CI was not estimable due to less number of subjects with events.

End point type	Secondary

End point timeframe:

Up to Week 27

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Endpoint was planned to be reported for the specified arms only.

End point values	Part 2: Daratumumab 8 mg/kg	Part 2: Daratumumab 16 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	42		
Units: Months				
median (confidence interval 95%)	2.4 (1.4 to 3.5)	5.6 (4.7 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Duration of Response as Assessed Using the Method of Kaplan-Meier

End point title	Part 2: Duration of Response as Assessed Using the Method of Kaplan-Meier[5]

End point description:

Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the International Myeloma Working Group (IMWG) criteria. Subset of All-Treated Analysis Set included all the subjects who had overall response in Part 2. Here "N" (number of subjects analyzed) signifies the number of subjects who were evaluable for this outcome measure. Here "99999" indicates that median and upper limit of CI was

not estimable due to insufficient number of subjects with events.

End point type	Secondary

End point timeframe:

Up to Week 27

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint was planned to be reported for the specified arms only.

End point values	Part 2: Daratumumab 8 mg/kg	Part 2: Daratumumab 16 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	15		
Units: Months				
median (full range (min-max))	6.9 (6.2 to 10.6)	99999 (5.6 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Progression-Free Survival

End point title	Part 2: Progression-Free Survival[6]

End point description:

Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first. All-Treated Analysis Set included all enrolled subjects who received at least 1 dose of study drug.

End point type	Secondary

End point timeframe:

Up to Week 27

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint was planned to be reported for the specified arms only.

End point values	Part 2: Daratumumab 8 mg/kg	Part 2: Daratumumab 16 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	42		
Units: Months				
median (confidence interval 95%)	2.4 (1.4 to 3.5)	5.6 (4.2 to 8.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Time to Response

End point title	Part 2: Time to Response[7]

End point description:

Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Time to VGPR (very good partial response) was defined as the time from the date of first dose of daratumumab to the date of initial documentation of VGPR response. The Kaplan-Meier method was used to estimate time to response. All-Treated analysis set included all enrolled subjects who received at least 1 dose of study drug. Here 'n' signifies number of subjects analyzed at specific time point. Here "99999" indicates no subject had VGPR or better response in daratumumab 8 mg/kg group. Hence, data was not analyzed.

End point type	Secondary

End point timeframe:

Up to Week 27

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint was planned to be reported for the specified arms only.

End point values	Part 2: Daratumumab 8 mg/kg	Part 2: Daratumumab 16 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	42		
Units: Months				
arithmetic mean (standard deviation)				
Time to first response (n=3, 15)	1.36 (± 0.774)	1.33 (± 0.995)		
Time to best response (n=3, 15)	1.36 (± 0.774)	2.46 (± 2.800)		
Time to VGPR or better response (n=0, 4)	99999 (± 99999)	0.49 (± 0.000)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Overall Survival

End point title	Part 2: Overall Survival[8]

End point description:

Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method. All-Treated Analysis Set included all enrolled subjects who received at least 1 dose of study drug. Here "99999" indicates CI was not estimable due to insufficient number of subjects with events.

End point type	Secondary

End point timeframe:

Approximately 3 years

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint was planned to be reported for the specified arms only.

End point values	Part 2: Daratumumab 8 mg/kg	Part 2: Daratumumab 16 mg/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	42		
Units: Months				
median (confidence interval 95%)	18.2 (7.5 to 22.6)	34.3 (19.9 to 99999)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to Week 28 (for Part 1) and approximately 2.5 years

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	18.0

Reporting groups

Reporting group title	Part 1: Daratumumab < 4 mg/kg

Reporting group description:

Subjects were administered with 7 full intravenous (IV) infusion of 0.005, 0.05, 0.1, 0.5, 1 and 2 milligram per kilogram body weight (mg/kg) daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1:Daratumumab 4 mg/kg

Reporting group description:

Subjects were administered with 7 full IV infusion of 4 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1:Daratumumab 8 mg/kg (Experimental)

Reporting group description:

Subjects were administered with 7 full IV infusion of 8 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1 - Daratumumab 16 mg/kg

Reporting group description:

Subjects were administered with 7 full IV infusion of 16 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 1 - Daratumumab 24 mg/kg

Reporting group description:

Subjects were administered with 7 full IV infusion of 24 mg/kg daratumumab once weekly, along with this subjects also received methylprednisolone 80 mg IV injection before first 2 infusions and 40 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Reporting group title	Part 2 - Daratumumab 8 mg/kg

Reporting group description:

Subjects were administered with 8 full IV infusions of 8 mg/kg daratumumab once weekly for 8 weeks, then every 2 weeks (q2w) for 16 weeks, then every 4 weeks (q4w) until the subject experienced disease progression or unmanageable toxicity whichever came first, along with this subjects also received methylprednisolone 100 mg IV before treatment and 20–25 mg methylprednisolone orally for 2 days after all full infusions.

Reporting group title	Part 2 - Daratumumab 16 mg/kg

Reporting group description:

Subjects were administered with 8 full IV infusions of 16 mg/kg daratumumab once weekly for 7 weeks, then every 2 weeks (q2w) for 14 weeks, then every 4 weeks (q4w) until the subject experienced disease progression or unmanageable toxicity whichever came first, along with this subjects also received methylprednisolone 100 mg IV before treatment and 20–25 mg methylprednisolone orally for 2 days after all full infusions. First 2 infusions were separated by 3 week washout period.

Serious adverse events	Part 1: Daratumumab < 4 mg/kg	Part 1:Daratumumab 4 mg/kg	Part 1:Daratumumab 8 mg/kg (Experimental)
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 20 (35.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Plasmacytoma			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest Pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema Peripheral			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Cytokine Release Syndrome			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			

subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional State			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood Creatinine Increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crossmatch Incompatible			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Free Haemoglobin Present			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
International Normalised Ratio Increased			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Limb Traumatic Amputation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal Compression Fracture			

subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial Fibrillation			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial Flutter			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient Ischaemic Attack			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vith Nerve Paralysis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Thrombocytopenia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic Function Abnormal			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back Pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone Pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporotic Fracture			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			

subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial Sepsis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes Zoster			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metapneumovirus Infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory Syncytial Virus Infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			

subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypomagnesaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 1 - Daratumumab 16 mg/kg	Part 1 - Daratumumab 24 mg/kg	Part 2 - Daratumumab 8 mg/kg
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 3 (66.67%)	2 / 3 (66.67%)	12 / 30 (40.00%)
number of deaths (all causes)	1	0	25
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Plasmacytoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema Peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			

subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Cytokine Release Syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional State			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood Creatinine Increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crossmatch Incompatible			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Free Haemoglobin Present			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
International Normalised Ratio Increased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Limb Traumatic Amputation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal Compression Fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial Fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial Flutter			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient Ischaemic Attack			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vith Nerve Paralysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic Function Abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone Pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporotic Fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial Sepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes Zoster			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metapneumovirus Infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	3 / 30 (10.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory Syncytial Virus Infection			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypomagnesaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 2 - Daratumumab 16 mg/kg		
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 42 (38.10%)		
number of deaths (all causes)	21		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Plasmacytoma			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest Pain			

subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oedema Peripheral			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Cytokine Release Syndrome			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Confusional State			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Blood Creatinine Increased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Crossmatch Incompatible			

subjects affected / exposed	3 / 42 (7.14%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Free Haemoglobin Present			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
International Normalised Ratio Increased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Limb Traumatic Amputation			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal Compression Fracture			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial Fibrillation			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrial Flutter			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Amnesia			

subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Transient Ischaemic Attack			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vith Nerve Paralysis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			

Hepatic Function Abnormal				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Musculoskeletal and connective tissue disorders				
Back Pain				
subjects affected / exposed	1 / 42 (2.38%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bone Pain				
subjects affected / exposed	1 / 42 (2.38%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Osteoporotic Fracture				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
Bacteraemia				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bacterial Sepsis				
subjects affected / exposed	1 / 42 (2.38%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Herpes Zoster				
subjects affected / exposed	2 / 42 (4.76%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Metapneumovirus Infection				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	3 / 42 (7.14%)			
occurrences causally related to treatment / all	1 / 3			
deaths causally related to treatment / all	0 / 1			
Respiratory Syncytial Virus Infection				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary Tract Infection				
subjects affected / exposed	0 / 42 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Varicella				
subjects affected / exposed	1 / 42 (2.38%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Metabolism and nutrition disorders				
Hypokalaemia				
subjects affected / exposed	1 / 42 (2.38%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hypomagnesaemia				
subjects affected / exposed	1 / 42 (2.38%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Part 1: Daratumumab < 4 mg/kg	Part 1:Daratumumab 4 mg/kg	Part 1:Daratumumab 8 mg/kg (Experimental)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	19 / 20 (95.00%)	3 / 3 (100.00%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal Cell Carcinoma			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Benign Neoplasm of Skin			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
Flushing			
subjects affected / exposed	2 / 20 (10.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Hot Flush			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	2 / 20 (10.00%)	0 / 3 (0.00%)	2 / 3 (66.67%)
occurrences (all)	2	0	2
Hypotension			
subjects affected / exposed	2 / 20 (10.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
General disorders and administration site conditions			
Chest Discomfort			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Chest Pain			
subjects affected / exposed	2 / 20 (10.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Chills			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fatigue			

subjects affected / exposed	2 / 20 (10.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Influenza Like Illness			
subjects affected / exposed	3 / 20 (15.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	4	0	0
Oedema Peripheral			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
subjects affected / exposed	7 / 20 (35.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	10	0	0
Immune system disorders			
Cytokine Release Syndrome			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypersensitivity			
subjects affected / exposed	1 / 20 (5.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	1	3	0
Reproductive system and breast disorders			
Prostatitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Cough			
subjects affected / exposed	4 / 20 (20.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	4	1	0
Dysphonia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Dyspnoea			
subjects affected / exposed	0 / 20 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	5	0
Epistaxis			

subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Laryngitis Allergic			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal Congestion			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal Pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Productive Cough			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinitis Allergic			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Throat Irritation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Throat Tightness			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Confusional State			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Investigations			
Blood Creatine Phosphokinase Increased			
subjects affected / exposed	0 / 20 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Electrocardiogram QT Prolonged			

subjects affected / exposed	5 / 20 (25.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	10	0	0
Free Haemoglobin Present			
subjects affected / exposed	4 / 20 (20.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	10	0	0
Haptoglobin Decreased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Lymphocyte Count Decreased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 20 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	3	0
Supraventricular Extrasystoles			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Tachycardia			
subjects affected / exposed	2 / 20 (10.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	3 / 20 (15.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	4	0	0
Dysgeusia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 20 (5.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	1	2	0
Hypoaesthesia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Paraesthesia			

subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Peripheral Sensory Neuropathy			
subjects affected / exposed	0 / 20 (0.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	4 / 20 (20.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	6	0	0
Haemolysis			
subjects affected / exposed	3 / 20 (15.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	4	0	0
Leukopenia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	2 / 20 (10.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Monocytopenia			
subjects affected / exposed	2 / 20 (10.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	8	1	0
Neutropenia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Thrombocytopenia			
subjects affected / exposed	3 / 20 (15.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	4	0	0
Eye disorders			
Ocular Hyperaemia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Vision Blurred			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			

Abdominal Pain			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Aphthous Stomatitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Diarrhoea			
subjects affected / exposed	1 / 20 (5.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Dry Mouth			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lip Oedema			
subjects affected / exposed	0 / 20 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Mouth Ulceration			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	2 / 20 (10.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	2	2	1
Oesophagitis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Stomatitis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 20 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0

Hepatobiliary disorders			
Hepatic Function Abnormal			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	3
Skin and subcutaneous tissue disorders			
Eczema Asteatotic			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 20 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hyperhidrosis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 20 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Rash			
subjects affected / exposed	1 / 20 (5.00%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	1	1	1
Renal and urinary disorders			
Pollakiuria			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Proteinuria			
subjects affected / exposed	9 / 20 (45.00%)	1 / 3 (33.33%)	3 / 3 (100.00%)
occurrences (all)	12	2	3
Renal Impairment			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 20 (10.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Back Pain			

subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Bone Pain			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Kyphosis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal Chest Pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal Pain			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain in Extremity			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Herpes Zoster			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	2 / 20 (10.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Oral Candidiasis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Sinusitis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Upper Respiratory Tract Infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary Tract Infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Viral Infection			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Vulvovaginal Candidiasis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Enzyme Abnormality			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Hyperglycaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Part 1 - Daratumumab 16 mg/kg	Part 1 - Daratumumab 24 mg/kg	Part 2 - Daratumumab 8 mg/kg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	3 / 3 (100.00%)	30 / 30 (100.00%)

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal Cell Carcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Benign Neoplasm of Skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Hot Flush			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	9
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chest Discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	6
Chest Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	9
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	13 / 30 (43.33%)
occurrences (all)	0	0	22
Influenza Like Illness			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	1	0	1

Oedema Peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	3
Pyrexia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	12 / 30 (40.00%)
occurrences (all)	6	0	16
Immune system disorders			
Cytokine Release Syndrome			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Hypersensitivity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	2
Reproductive system and breast disorders			
Prostatitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 30 (3.33%)
occurrences (all)	0	1	1
Cough			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	6 / 30 (20.00%)
occurrences (all)	0	1	10
Dysphonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	8 / 30 (26.67%)
occurrences (all)	0	0	14
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	3
Laryngitis Allergic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	3

Nasal Congestion			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	4 / 30 (13.33%)
occurrences (all)	0	1	4
Oropharyngeal Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Productive Cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	3
Rhinitis Allergic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	12 / 30 (40.00%)
occurrences (all)	0	0	14
Throat Irritation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Throat Tightness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Confusional State			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	4 / 30 (13.33%)
occurrences (all)	0	0	4
Investigations			
Blood Creatine Phosphokinase Increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT Prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Free Haemoglobin Present			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Haptoglobin Decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Lymphocyte Count Decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Supraventricular Extrasystoles			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	5 / 30 (16.67%)
occurrences (all)	0	0	8
Dysgeusia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	4
Hypoaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Peripheral Sensory Neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	5 / 30 (16.67%)
occurrences (all)	0	0	5
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Haemolysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Monocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Eye disorders			
Ocular Hyperaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Vision Blurred			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Aphthous Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Constipation			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	4 / 30 (13.33%)
occurrences (all)	0	0	4
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	9 / 30 (30.00%)
occurrences (all)	0	1	12
Dry Mouth			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	2
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	3
Lip Oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Mouth Ulceration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	4 / 30 (13.33%)
occurrences (all)	0	0	5
Oesophagitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	4
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	5 / 30 (16.67%)
occurrences (all)	0	1	6
Hepatobiliary disorders			
Hepatic Function Abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Eczema Asteatotic			

subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	2	0	0
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	3
Pruritus			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 30 (6.67%)
occurrences (all)	2	0	3
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	4 / 30 (13.33%)
occurrences (all)	0	0	5
Renal and urinary disorders			
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 30 (0.00%)
occurrences (all)	1	1	0
Renal Impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	4 / 30 (13.33%)
occurrences (all)	0	0	5
Back Pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	3 / 30 (10.00%)
occurrences (all)	0	1	4
Bone Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	6 / 30 (20.00%)
occurrences (all)	0	0	7
Kyphosis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal Chest Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	3
Musculoskeletal Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	3
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	6 / 30 (20.00%)
occurrences (all)	0	0	11
Pain in Extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Herpes Zoster			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	4 / 30 (13.33%)
occurrences (all)	0	0	4
Nasopharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	7 / 30 (23.33%)
occurrences (all)	0	2	15
Oral Candidiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	3
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Sinusitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Upper Respiratory Tract Infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	8 / 30 (26.67%)
occurrences (all)	1	0	10

Urinary Tract Infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	3
Viral Infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal Candidiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Enzyme Abnormality			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Part 2 - Daratumumab 16 mg/kg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	41 / 42 (97.62%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal Cell Carcinoma			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	6		
Benign Neoplasm of Skin			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		

Vascular disorders			
Flushing			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Hot Flush			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Hypotension			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Chest Discomfort			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Chest Pain			
subjects affected / exposed	5 / 42 (11.90%)		
occurrences (all)	5		
Chills			
subjects affected / exposed	5 / 42 (11.90%)		
occurrences (all)	5		
Fatigue			
subjects affected / exposed	19 / 42 (45.24%)		
occurrences (all)	22		
Influenza Like Illness			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Oedema Peripheral			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Pyrexia			
subjects affected / exposed	9 / 42 (21.43%)		
occurrences (all)	13		
Immune system disorders			

Cytokine Release Syndrome			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Hypersensitivity			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Reproductive system and breast disorders			
Prostatitis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	11 / 42 (26.19%)		
occurrences (all)	18		
Dysphonia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	7 / 42 (16.67%)		
occurrences (all)	7		
Epistaxis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Laryngitis Allergic			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Nasal Congestion			
subjects affected / exposed	7 / 42 (16.67%)		
occurrences (all)	8		
Oropharyngeal Pain			
subjects affected / exposed	5 / 42 (11.90%)		
occurrences (all)	7		
Productive Cough			

subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Rhinitis Allergic			
subjects affected / exposed	10 / 42 (23.81%)		
occurrences (all)	10		
Throat Irritation			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Throat Tightness			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Psychiatric disorders			
Confusional State			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Insomnia			
subjects affected / exposed	5 / 42 (11.90%)		
occurrences (all)	6		
Investigations			
Blood Creatine Phosphokinase Increased			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Electrocardiogram QT Prolonged			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	2		
Free Haemoglobin Present			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Haptoglobin Decreased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Lymphocyte Count Decreased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Cardiac disorders			

Palpitations			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	2		
Supraventricular Extrasystoles			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Dizziness			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	6		
Dysgeusia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	5		
Hypoaesthesia			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Paraesthesia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	2		
Peripheral Sensory Neuropathy			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Haemolysis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Leukopenia			

subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	5		
Lymphopenia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Monocytopenia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	4		
Thrombocytopenia			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Eye disorders			
Ocular Hyperaemia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Vision Blurred			
subjects affected / exposed	5 / 42 (11.90%)		
occurrences (all)	5		
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Aphthous Stomatitis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	4		
Diarrhoea			
subjects affected / exposed	6 / 42 (14.29%)		
occurrences (all)	14		
Dry Mouth			

subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	3		
Lip Oedema			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Mouth Ulceration			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	10 / 42 (23.81%)		
occurrences (all)	14		
Oesophagitis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Stomatitis			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Hepatobiliary disorders			
Hepatic Function Abnormal			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Eczema Asteatotic			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Erythema			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Hyperhidrosis			

subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Pruritus			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Rash			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Renal and urinary disorders			
Pollakiuria			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Proteinuria			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Renal Impairment			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	8 / 42 (19.05%)		
occurrences (all)	9		
Back Pain			
subjects affected / exposed	14 / 42 (33.33%)		
occurrences (all)	16		
Bone Pain			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	4		
Kyphosis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Musculoskeletal Chest Pain			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	6		
Musculoskeletal Pain			

subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	5		
Myalgia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Pain in Extremity			
subjects affected / exposed	6 / 42 (14.29%)		
occurrences (all)	7		
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Herpes Zoster			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Nasopharyngitis			
subjects affected / exposed	16 / 42 (38.10%)		
occurrences (all)	26		
Oral Candidiasis			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Pneumonia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	4		
Upper Respiratory Tract Infection			
subjects affected / exposed	11 / 42 (26.19%)		
occurrences (all)	20		
Urinary Tract Infection			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Viral Infection			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		

Vulvovaginal Candidiasis subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0		
Metabolism and nutrition disorders Decreased Appetite subjects affected / exposed occurrences (all) Enzyme Abnormality subjects affected / exposed occurrences (all) Hypercalcaemia subjects affected / exposed occurrences (all) Hyperglycaemia subjects affected / exposed occurrences (all) Hyponatraemia subjects affected / exposed occurrences (all)	 4 / 42 (9.52%) 4 0 / 42 (0.00%) 0 0 / 42 (0.00%) 0 5 / 42 (11.90%) 13 1 / 42 (2.38%) 2		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported